Evogene, which develops genetically enhanced seeds to elevate crop performance and productivity, raised $74 million by offering 5.0 million shares at $14.75, below the expected price of $17.16, which was the last reported sale price of its shares on the Tel Aviv Stock Exchange. Evogene plans to list on the NYSE under the symbol EVGN. The company initially filed confidentially on April 26, 2013. Credit Suisse and Deutsche Bank acted as lead managers on the deal.
